Torrent Pharmaceuticals Limited (TORNTPHARM)

Loading page…

Torrent Pharmaceuticals Limited (TORNTPHARM) · mywealthgrid

About

Torrent Pharmaceuticals Limited is a large-cap pharmaceutical company with a market cap of ₹1,63,548.72 Cr, generating ₹2,600–4,900 Cr in quarterly revenue. Operating margins of 32–39% and ROE of 27.07% reflect operational efficiency and profitable capital deployment. The stock's 34% one-year return and PE of 74.99 indicate strong market confidence but also elevated growth expectations.

Founded: 1959
Face value: ₹5

Market cap

₹1,61,325 Cr

P/E

74.0×

P/B

19.2×

Dividend yield

0.9%

ROE

27.1%

ROCE

14.5%

Debt / equity

1.76

OPM

32.6%

EPS (TTM)

₹64.5

Book value

₹248.2

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

High valuation (PE 74.99) embeds significant growth expectations; any earnings disappointment or margin pressure could trigger sharp stock correction.
Elevated leverage (D/E 1.76) limits financial flexibility; rising interest rates or slowing revenue growth could compress net profit despite current ROE of 27%.
Operating margin volatility of 6.5 percentage points (32.31%–38.81% across recent quarters) signals exposure to input costs, forex fluctuations, or product-mix shifts—verify sustainability.
Pharmaceutical pricing pressure from regulators erodes margins on high-volume generics; verify Torrent's exposure to price-controlled segments and product mix.

Generated analysis · source review pending

Growth drivers

EPS of ₹14.87 in Jun 2026 nearing the high end of recent range (₹11.51–18.77); verify if this reflects a structural improvement in earnings run-rate.
Operating margins above 35% in four recent quarters (37.83%, 36.67%, 38.48%, 38.81%) suggest operational improvements or cost management; verify source and durability.
ROE of 27.07% with manageable D/E of 1.76 enables reinvestment without major dilution; verify capex plans and new-product pipeline for growth potential.
Revenue scaling to ₹4,900+ Cr in recent quarters vs. lows of ₹2,600 Cr suggests market opportunity or improved order timing; verify if ₹4+ Cr quarterly revenue becomes normalized.

Generated analysis · source review pending

2,528 historical price candles were omitted because the exchange source has not been verified.

₹4,767.3-2.6%1Y

Quick read

rule-based

Pros

+Strong return on equity of 26.3% (3-yr avg)
+High return on capital employed of 23.8%
+Healthy operating margin of 32.6%
+Dividend payout of 68.3% of profit
+High promoter holding of 68.3% with no pledge

Cons

−Heavily leveraged (debt/equity 1.8)
−Expensive at 74× trailing earnings
−Trading at 19.2× book value

Research score

Structured signal from quality, growth, valuation and momentum.

40/100

Business quality: 56
Growth

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Part ofNIFTY NEXT 50 NIFTY 100 NIFTY 200 NIFTY 500 NIFTY TOTAL MARKET

Screen this industry

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	6,002	7,673	7,939	8,005	8,508	9,620	10,728	11,516	13,980
COGS	1,674	2,219	2,167	2,147	2,443	2,735	2,686	2,776	3,388
Gross profit	4,328	5,454	5,772	5,858	6,065	6,885	8,042	8,740	10,592
	2,979	3,470	3,602	3,373	3,634	4,043	4,674	5,019	6,033
	1,349	1,984	2,170	2,485	2,431	2,842	3,368	3,721	4,559
OPM %	22.5%	25.9%	27.3%	31%	28.6%	29.5%	31.4%	32.3%	32.6%
Depreciation	409	618	654	658	662	707	808	795	1,119
Interest	308	504	451	358	255	333	354	252	385
	299	-300	122	57	-288	45	146	-1	-183
Profit before tax	931	562	1,187	1,526	1,226	1,847	2,352	2,673	2,872
Tax	253	126	162	274	449	602	696	762	734
Tax %	27.2%	22.4%	13.7%	18%	36.6%	32.6%	29.6%	28.5%	25.6%
	678	436	1,025	1,252	777	1,245	1,656	1,911	2,138
PAT margin %	11.3%	5.7%	12.9%	15.6%	9.1%	12.9%	15.4%	16.6%	15.3%
EPS (₹)	40.1	25.8	60.6	74	45.9	36.8	48.9	56.5	63.9
EPS adjusted (₹)	20	12.9	30.3	37	23	36.8	49	56.5	64
	34.9%	124.1%	28.1%	47.3%	104.5%	59.8%	57.2%	56.7%	59.4%
Annual report	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	85	85	85	85	85	85	85	169	169	169	169
Reserves	2,558	3,409	4,538	4,640	4,739	5,753	5,868	6,029	6,687	7,422	8,220
Minority interest	—	—	1	—	—	—	—	—	—	—	9,196
	2,492	1,853	5,737	4,847	4,366	4,825	4,018	5,297	3,938	3,026	14,798
	2,829	3,710	3,883	4,550	4,820	3,412	3,129	3,517	4,267	4,373	11,929
Total equity & liabilities	7,964	9,058	14,243	14,121	14,010	14,075	13,100	15,012	15,061	14,990	44,312
	2,794	2,859	7,855	7,748	7,398	6,939	6,295	8,122	8,138	7,946	33,179
CWIP	678	1,042	423	479	577	744	544	688	281	367	457
Investments	299	780	492	353	2	181	226	199	173	156	962
	4,194	4,378	5,473	5,540	6,033	6,211	6,034	6,003	6,469	6,521	9,714
Total assets	7,964	9,058	14,243	14,121	14,010	14,075	13,100	15,012	15,061	14,990	44,312

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	71.1%	72.7%	73.2%	71.3%	71.6%	75%	75.9%	75.8%
EBITDA margin %	25.9%	27.3%	31%	28.6%	29.5%	31.4%	32.3%	32.6%
EBIT margin %	17.8%	19.1%	22.8%	20.8%	22.2%	23.9%	25.4%	24.6%
PAT margin %	5.7%	12.9%	15.6%	9.1%	12.9%	15.4%	16.6%	15.3%
Working capital
Receivable days	68	76	69	70	74	63	59	79
Inventory days	318	362	456	368	298	310	334	338
Payable days	345	345	3	250	224	284	239	254
NWC days	42	93	522	188	147	89	154	163
Leverage
Current ratio	0.98	0.91	1.13	1.17	0.98	1.03	1.19	1.13
Debt to EBITDA	2.44	2.01	1.94	1.65	1.86	1.17	0.81	3.25
Debt to equity	1.03	0.91	0.83	0.67	0.85	0.57	0.4	1.76
Interest coverage	2.8	3.6	5.3	7.7	6.5	7.4	11.7	8.7
Asset turnover	0.54	0.57	0.57	0.65	0.64	0.71	0.77	0.32
Return ratios
Return on assets %	3.1%	7.3%	8.9%	5.9%	8.3%	11%	12.7%	4.8%
Return on capital employed %	15.8%	18.7%	21.2%	22%	23.9%	27.3%	29.6%	14.5%
Return on equity %	9.2%	21.3%	21.4%	13.1%	20.1%	24.2%	25.2%	25.5%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	71.25%	71.25%	71.25%	71.25%	71.25%	68.31%	68.31%	68.31%	68.31%	68.31%	68.31%	68.31%
	13.15%	14.09%	14.14%	14.22%	14.46%	16.17%	16.31%	16.09%	15.92%	16.13%	16.18%	15.44%
	8%	7.21%	7.26%	7.27%	7.08%	8.35%	8.35%	8.65%	9.18%	9.04%	9.06%	9.73%
	0%	0%	0%	0%	0%	0%	0%	0%	0.1%	0.1%	0%	0.1%
	7.6%	7.45%	7.35%	7.26%	7.21%	7.17%	7.03%	6.95%	6.49%	6.42%	6.45%	6.42%
No. of shareholders	—	—	—	—	—	—	—	—	78,226	76,214	83,811	85,776

Promoter holding down 2.94 percentage points since Sep 2023.

46 deals · 31 Aug 2021 – 23 Jan 2025

Date	Client	Type	Venue	Side	Quantity	Price	Value
23 Jan 2025	UBS AG	Block	NSE	Buy	44,810	₹3,252.10	₹14.57 Cr
23 Jan 2025	UBS PRINCIPAL CAPITAL ASIA LIMITED	Block	NSE	Sell	44,810	₹3,252.10	₹14.57 Cr
30 Oct 2024	TORRENT INVESTMENTS PRIVATE LIMITED	Bulk	BSE	Sell	49,72,020	₹3,104.40	₹1,543.51 Cr
30 Oct 2024	TORRENT INVESTMENTS PRIVATE LIMITED	Bulk	BSE	Sell	49,72,020	₹3,103.07	₹1,542.85 Cr
7 Mar 2024	SEB FUND 3 SEB PENSION FUND	Block	NSE	Sell	63,294	₹2,691.20	₹17.03 Cr
7 Mar 2024	SEB ASIENFOND EX JAPAN	Block	NSE	Buy	63,294	₹2,691.20	₹17.03 Cr
25 Jan 2024	BNP PARIBAS ARBITRAGE	Block	BSE	Sell	4,74,629	₹2,507.05	₹118.99 Cr
25 Jan 2024	SOCIETE GENERALE	Block	BSE	Buy	4,74,629	₹2,507.05	₹118.99 Cr
25 Jan 2024	BNP PARIBAS ARBITRAGE	Block	BSE	Sell	55,561	₹2,507.05	₹13.93 Cr
25 Jan 2024	MARSHALLWACEINVESTMENTSTRATEGIESMARKETNEUTRALTOPSFUND	Block	BSE	Buy	47,322	₹2,507.05	₹11.86 Cr

1–10 of 46

1 / 5

Mr. Samir Uttamlal MehtaExecutive Director-Chairperson-CEO-MD
Ms. Ameera Sushil ShahNon-Executive - Independent Director
Sudhir MenonChief Financial Officer
Ms. Nayantara BaliNon-Executive - Independent Director
Mr. Manish Mahendra ChoksiNon-Executive - Independent Director
Mr. Aman MehtaExecutive Director-MD
Mr. Nikhil Nirvan KhattauNon-Executive - Independent Director
Mr. Jinal Sudhirbhai MehtaNon-Executive - Non Independent Director
Mr. Chintan TrivediCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

End of day 30 Sept 2026 · underlying ₹4,800.0 · volume and open interest in contracts

3

Expiry	Close	Chg	% Chg	Settlement	Open interest	Change in OI	Volume	Lot size
27 Oct 2026	₹4,832.0	-122.5	-2.5%	₹4,832.0	25,549	+215	2,229	125
23 Nov 2026	₹4,852.5	-118	-2.4%	₹4,852.5	3,112	+22	48	125
29 Dec 2026	₹4,910.0	-57	-1.1%	₹4,875.8	1	+1	2	125

Open the chart icon on a row for that contract's close over 103 stored sessions, with open interest as bars beneath it.

30

27 Oct 2026 23 Nov 2026 29 Dec 2026

Calls				Strike	Puts
OI	Chg OI	Volume	LTP	—	LTP	Volume	Chg OI	OI
18	0	0	₹822.0	4,100

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

159

across 20 fund houses

Held by these funds

4.42%

of the company's equity

All mutual funds

4.94%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

159 schemes · 20 fund houses

		Shares
Portfolio of Kotak Mid Cap FundNEW	Kotak Mahindra Mutual Fund	17.3 L	876.5	1.23%	0.511%	—
Small Cap Fund	Axis Mutual Fund	14.86 L	752.64	2.39%	0.439%	-36,560
Large Cap Fund	Axis Mutual Fund	7.83 L	396.59	1.26%	0.231%	-0
ELSS- Tax Saver Fund	Axis Mutual Fund	6.47 L	327.6	1%	0.191%	-76,209
Franklin India Large Cap Fund (Formerly known as Franklin India Bluechip Fund)^	Franklin Templeton Mutual Fund	5.9 L	299.01	3.99%	0.174%	-0
Nifty Next 50 Index Fund	ICICI Prudential Mutual Fund	5.84 L	295.82	2.92%	0.173%	+9,314
Healthcare Opportunities Fund	SBI Mutual Fund	5.4 L	273.56	4.72%	0.16%	+40,000
ETF NIFTY NEXT 50 JUNIOR BEES	Nippon India Mutual Fund	5.18 L	262.28	2.92%	0.153%	+16,665

1–8 of 159

1 / 20

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Jul 2026TranscriptAI SummaryPPTREC
May 2026Transcript AI Summary PPT REC

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

27 announcementsExport CSV

28 Sept 2026, 12:00 pmCompany Update

Announcement under Regulation 30 (LODR)-Updates on Acquisition

Acquisition PDF

28 Sept 2026, 11:27 amInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

10 Sept 2026, 9:26 pmCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Analyst / Investor Meet PDF

9 Sept 2026, 5:48 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

7 Sept 2026, 7:16 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot

Postal Ballot PDF

7 Sept 2026, 7:14 pmAGM/EGM

Torrent Pharmaceuticals Ltd - 500420 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report

Postal Ballot PDF

11 Aug 2026, 4:26 pmCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Analyst / Investor Meet PDF

11 Aug 2026, 2:51 pmCompany Update

Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - ESG Rating

General PDF

Date	Category	Subject	Filing
28 Sept 2026, 12:00 pm	Company Update Acquisition	Announcement under Regulation 30 (LODR)-Updates on Acquisition	PDF
28 Sept 2026, 11:27 am	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	71.1%	72.7%	73.2%	71.3%	71.6%	75%	75.9%	75.8%
EBITDA margin %	25.9%	27.3%	31%	28.6%	29.5%	31.4%	32.3%	32.6%
EBIT margin %	17.8%	19.1%	22.8%	20.8%	22.2%	23.9%	25.4%	24.6%
PAT margin %	5.7%	12.9%	15.6%	9.1%	12.9%	15.4%	16.6%	15.3%
Working capital
Receivable days	68	76	69	70	74	63	59	79
Inventory days	318	362	456	368	298	310	334	338
Payable days	345	345	3	250	224	284	239	254
NWC days	42	93	522	188	147	89	154	163
Leverage
Current ratio	0.98	0.91	1.13	1.17	0.98	1.03	1.19	1.13
Debt to EBITDA	2.44	2.01	1.94	1.65	1.86	1.17	0.81	3.25
Debt to equity	1.03	0.91	0.83	0.67	0.85	0.57	0.4	1.76
Interest coverage	2.8	3.6	5.3	7.7	6.5	7.4	11.7	8.7
Asset turnover	0.54	0.57	0.57	0.65	0.64	0.71	0.77	0.32
Return ratios
Return on assets %	3.1%	7.3%	8.9%	5.9%	8.3%	11%	12.7%	4.8%
Return on capital employed %	15.8%	18.7%	21.2%	22%	23.9%	27.3%	29.6%	14.5%
Return on equity %	9.2%	21.3%	21.4%	13.1%	20.1%	24.2%	25.2%	25.5%

Calls	Strike	Puts
18	0	0	₹822.0	4,100

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	2,742	1,009	894	1,232	1,579	2,011	1,803	2,368	3,266	2,585	3,023
	-838	-787	-4,707	-373	-81	-449	-198	-2,356	-168	-540	-12,713
	-1,435	-193	3,417	-928	-1,555	-1,656	-1,781	77	-2,779	-2,298	10,151
Net cash flow	469	29	-395	-69	-57	-94	-176	89	319	-253	461
Free cash flow	2,143	522	103	616	1,233	1,676	1,600	1,794	2,833	1,974	2,346
CFO / Operating profit %	—	—	66.3%	62.1%	72.8%	80.9%	74.2%	83.3%	97%	69.5%	66.3%

Torrent Pharmaceuticals Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

3

30

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

Announcements

3

30

37

1

2

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Compounded sales growth

Compounded profit growth

Return on equity

Torrent Pharmaceuticals Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Futures3

Option chain30

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

Announcements

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

Futures3

Option chain30

Dividends37

Board meetings1

Bonus issues2

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

3

30

3

30

37

1

2